DE19632423A1 - Thienopyrimidine - Google Patents

Thienopyrimidine

Info

Publication number
DE19632423A1
DE19632423A1 DE19632423A DE19632423A DE19632423A1 DE 19632423 A1 DE19632423 A1 DE 19632423A1 DE 19632423 A DE19632423 A DE 19632423A DE 19632423 A DE19632423 A DE 19632423A DE 19632423 A1 DE19632423 A1 DE 19632423A1
Authority
DE
Germany
Prior art keywords
pyrimidine
chloro
pyridin
thieno
methylthieno
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19632423A
Other languages
German (de)
English (en)
Inventor
Rochus Dr Jonas
Pierre Prof Dr Schelling
Franz-Werner Dr Kluxen
Maria Christadler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Priority to DE19632423A priority Critical patent/DE19632423A1/de
Priority to NZ334600A priority patent/NZ334600A/xx
Priority to ES97940047T priority patent/ES2191192T3/es
Priority to PL97331538A priority patent/PL190174B1/pl
Priority to KR10-1999-7001153A priority patent/KR100502271B1/ko
Priority to AT97940047T priority patent/ATE233265T1/de
Priority to UA99031300A priority patent/UA55421C2/uk
Priority to US09/230,806 priority patent/US6110920A/en
Priority to DE59709404T priority patent/DE59709404D1/de
Priority to RU99104796/04A priority patent/RU2199541C2/ru
Priority to PCT/EP1997/004139 priority patent/WO1998006722A1/de
Priority to EP97940047A priority patent/EP0920431B1/de
Priority to AU42035/97A priority patent/AU725227B2/en
Priority to IL12850497A priority patent/IL128504A/xx
Priority to CA002263561A priority patent/CA2263561C/en
Priority to SK164-99A priority patent/SK282823B6/sk
Priority to CN97197179A priority patent/CN1081638C/zh
Priority to HK00100583.3A priority patent/HK1021731B/xx
Priority to DK97940047T priority patent/DK0920431T3/da
Priority to CZ1999448A priority patent/CZ287772B6/cs
Priority to TR1999/00308T priority patent/TR199900308T2/xx
Priority to SI9730518T priority patent/SI0920431T1/xx
Priority to JP50934398A priority patent/JP4405593B2/ja
Priority to HU0001607A priority patent/HUP0001607A3/hu
Priority to PT97940047T priority patent/PT920431E/pt
Priority to BR9711062A priority patent/BR9711062A/pt
Priority to TW086111481A priority patent/TW359672B/zh
Priority to ZA9707156A priority patent/ZA977156B/xx
Priority to ARP970103649A priority patent/AR009052A1/es
Publication of DE19632423A1 publication Critical patent/DE19632423A1/de
Priority to NO990643A priority patent/NO990643D0/no
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE19632423A 1996-08-12 1996-08-12 Thienopyrimidine Withdrawn DE19632423A1 (de)

Priority Applications (30)

Application Number Priority Date Filing Date Title
DE19632423A DE19632423A1 (de) 1996-08-12 1996-08-12 Thienopyrimidine
CN97197179A CN1081638C (zh) 1996-08-12 1997-07-30 噻吩并嘧啶化合物
SK164-99A SK282823B6 (sk) 1996-08-12 1997-07-30 Derivát tienopyrimidínu, spôsob jeho prípravy a farmaceutický prostriedok, ktorý ho obsahuje
PL97331538A PL190174B1 (pl) 1996-08-12 1997-07-30 Nowe związki, tienopirymidyny, sposób ich wytwarzania oraz preparat farmaceutyczny
KR10-1999-7001153A KR100502271B1 (ko) 1996-08-12 1997-07-30 티에노피리미딘
AT97940047T ATE233265T1 (de) 1996-08-12 1997-07-30 Thienopyrimidine
UA99031300A UA55421C2 (uk) 1996-08-12 1997-07-30 Тієнопіримідини, спосіб їх одержання (варіанти), фармацевтична композиція та спосіб її одержання
US09/230,806 US6110920A (en) 1996-08-12 1997-07-30 Thienopyrimidines
DE59709404T DE59709404D1 (en) 1996-08-12 1997-07-30 Thienopyrimidine
RU99104796/04A RU2199541C2 (ru) 1996-08-12 1997-07-30 Тиенопиримидины, способ их получения (варианты), фармацевтическая композиция и способ ее получения
PCT/EP1997/004139 WO1998006722A1 (de) 1996-08-12 1997-07-30 Thienopyrimidine
EP97940047A EP0920431B1 (de) 1996-08-12 1997-07-30 Thienopyrimidine
AU42035/97A AU725227B2 (en) 1996-08-12 1997-07-30 Thienopyrimidines
IL12850497A IL128504A (en) 1996-08-12 1997-07-30 2-HETEROARYL-N-PHENYL (ALKYL) THIENO [2,3-d] PYRIMIDIN-4-AMINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CA002263561A CA2263561C (en) 1996-08-12 1997-07-30 Thienopyrimidines
NZ334600A NZ334600A (en) 1996-08-12 1997-07-30 Thienopyrimidines inhibiting phosphodiesterase V for treating cardiovascular disease and impotency
CZ1999448A CZ287772B6 (en) 1996-08-12 1997-07-30 Thienopyrimidine derivative, process of its preparation and pharmaceutical preparation in which it is comprised
ES97940047T ES2191192T3 (es) 1996-08-12 1997-07-30 Tienopirimidinas.
DK97940047T DK0920431T3 (da) 1996-08-12 1997-07-30 Thienopyrimidiner.
HK00100583.3A HK1021731B (en) 1996-08-12 1997-07-30 Thienopyrimidines
TR1999/00308T TR199900308T2 (xx) 1996-08-12 1997-07-30 Tiyenopirimidinler
SI9730518T SI0920431T1 (en) 1996-08-12 1997-07-30 Thienopyrimidines
JP50934398A JP4405593B2 (ja) 1996-08-12 1997-07-30 チエノピリミジン類
HU0001607A HUP0001607A3 (en) 1996-08-12 1997-07-30 Thienopyrimidine derivatives, pharmaceutical compositions containing them, process for their preparation and use of the compounds
PT97940047T PT920431E (pt) 1996-08-12 1997-07-30 Tienopirimidinas
BR9711062A BR9711062A (pt) 1996-08-12 1997-07-30 Tienopirimidinas
TW086111481A TW359672B (en) 1996-08-12 1997-08-11 Thienopyrimidines ad phosphodiesterase V antagonists, process for the production thereof and pharmaceutical compositions containing the same
ZA9707156A ZA977156B (en) 1996-08-12 1997-08-11 Thienopyrimidines.
ARP970103649A AR009052A1 (es) 1996-08-12 1997-08-12 Tienopirimidinas, un procedimiento para su preparacion, empleo de las mismas para preparar un medicamento, preparaciones farmaceuticas que lascontienen y un procedimiento para obtener estas preparaciones farmaceuticas
NO990643A NO990643D0 (no) 1996-08-12 1999-02-11 Tienopyrimidiner

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19632423A DE19632423A1 (de) 1996-08-12 1996-08-12 Thienopyrimidine

Publications (1)

Publication Number Publication Date
DE19632423A1 true DE19632423A1 (de) 1998-02-19

Family

ID=7802392

Family Applications (2)

Application Number Title Priority Date Filing Date
DE19632423A Withdrawn DE19632423A1 (de) 1996-08-12 1996-08-12 Thienopyrimidine
DE59709404T Expired - Lifetime DE59709404D1 (en) 1996-08-12 1997-07-30 Thienopyrimidine

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE59709404T Expired - Lifetime DE59709404D1 (en) 1996-08-12 1997-07-30 Thienopyrimidine

Country Status (28)

Country Link
US (1) US6110920A (cg-RX-API-DMAC7.html)
EP (1) EP0920431B1 (cg-RX-API-DMAC7.html)
JP (1) JP4405593B2 (cg-RX-API-DMAC7.html)
KR (1) KR100502271B1 (cg-RX-API-DMAC7.html)
CN (1) CN1081638C (cg-RX-API-DMAC7.html)
AR (1) AR009052A1 (cg-RX-API-DMAC7.html)
AT (1) ATE233265T1 (cg-RX-API-DMAC7.html)
AU (1) AU725227B2 (cg-RX-API-DMAC7.html)
BR (1) BR9711062A (cg-RX-API-DMAC7.html)
CA (1) CA2263561C (cg-RX-API-DMAC7.html)
CZ (1) CZ287772B6 (cg-RX-API-DMAC7.html)
DE (2) DE19632423A1 (cg-RX-API-DMAC7.html)
DK (1) DK0920431T3 (cg-RX-API-DMAC7.html)
ES (1) ES2191192T3 (cg-RX-API-DMAC7.html)
HU (1) HUP0001607A3 (cg-RX-API-DMAC7.html)
IL (1) IL128504A (cg-RX-API-DMAC7.html)
NO (1) NO990643D0 (cg-RX-API-DMAC7.html)
NZ (1) NZ334600A (cg-RX-API-DMAC7.html)
PL (1) PL190174B1 (cg-RX-API-DMAC7.html)
PT (1) PT920431E (cg-RX-API-DMAC7.html)
RU (1) RU2199541C2 (cg-RX-API-DMAC7.html)
SI (1) SI0920431T1 (cg-RX-API-DMAC7.html)
SK (1) SK282823B6 (cg-RX-API-DMAC7.html)
TR (1) TR199900308T2 (cg-RX-API-DMAC7.html)
TW (1) TW359672B (cg-RX-API-DMAC7.html)
UA (1) UA55421C2 (cg-RX-API-DMAC7.html)
WO (1) WO1998006722A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA977156B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2261863C2 (ru) * 2000-06-29 2005-10-10 Мерк Патент Гмбх 2-аминоалкилтиено[2,3-d]пиримидины, способ их получения, лекарственный препарат и способ его получения

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19819023A1 (de) * 1998-04-29 1999-11-04 Merck Patent Gmbh Thienopyrimidine
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
WO2000059912A1 (en) * 1999-03-30 2000-10-12 Nippon Soda Co., Ltd. Thienopyrimidine compounds and salts thereof and process for the preparation of the same
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
DE19950647A1 (de) * 1999-10-21 2001-04-26 Merck Patent Gmbh Imidazolderivate als Phosphodiesterase VII-Hemmer
CA2423981A1 (en) * 2000-09-29 2003-03-28 Kimiko Ichikawa Thienopyrimidine compounds and salts thereof and process for the preparation of the same
BR0206853A (pt) * 2001-02-02 2004-01-13 Merck Patent Ges Mit Beschroen Formulação farmacêutica compreendendo pirazolo[4,3-d]pirimidinas e antagonistas de receptor de endotelina ou tienopirimidinas e antagonistas de receptor de endotelina
WO2002083631A1 (en) 2001-04-13 2002-10-24 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
MXPA03009925A (es) * 2001-04-30 2004-06-30 Bayer Pharmaceuticals Corp Nuevas tiofeno [2,3-d]pirimidinas 4-amino-5,6-sustituidas.
NZ531375A (en) * 2001-09-04 2005-06-24 Akzo Nobel Nv Glycine-substituted thieno [2,3-d]pyrimidines with combined LH and FSH agonistic activity may be used to treat fertility disorders
JPWO2003035653A1 (ja) * 2001-10-26 2005-02-10 日本曹達株式会社 ピリドチエノピリミジン化合物およびその塩
US7153412B2 (en) 2001-12-28 2006-12-26 Kabushiki Kaisha Toyota Chuo Kenkyusho Electrodes, electrochemical elements, gas sensors, and gas measurement methods
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
TW200410975A (en) * 2002-09-26 2004-07-01 Nihon Nohyaku Co Ltd New pesticide and method for using it, new substituted thienopyrimidine derivative, its intermediate, and method for producing it
GB0320300D0 (en) * 2003-08-29 2003-10-01 Cancer Rec Tech Ltd Pyrimidothiophene compounds
DE10351436A1 (de) * 2003-11-04 2005-06-09 Merck Patent Gmbh Verwendung von Thienopyrimidinen
GB0420719D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
TWI417095B (zh) * 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc 1,4-二取代之3-氰基-吡啶酮衍生物及其作為mGluR2-受體之正向異位性調節劑之用途
TW200845978A (en) * 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) * 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
US9603848B2 (en) 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
EP2203439B1 (en) 2007-09-14 2011-01-26 Ortho-McNeil-Janssen Pharmaceuticals, Inc. 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-ý1, 4'¨bipyridinyl-2'-ones
EP2205565B1 (en) * 2007-09-14 2013-04-17 Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones
WO2009033702A1 (en) 2007-09-14 2009-03-19 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
EP2220083B1 (en) * 2007-11-14 2017-07-19 Janssen Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
US20100227853A1 (en) * 2008-04-18 2010-09-09 Trustees Of Boston College Inhibitors of cyclic amp phosphodiesterases
KR101523126B1 (ko) 2008-07-31 2015-05-26 세노믹스, 인코포레이티드 단맛 향상제의 제조 방법 및 중간체
ES2439291T3 (es) 2008-09-02 2014-01-22 Janssen Pharmaceuticals, Inc. Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos
JP5656848B2 (ja) 2008-10-16 2015-01-21 ジャンセン ファーマシューティカルズ, インコーポレイテッド. 代謝型グルタミン酸受容体モジュレーターとしてのインドールおよびベンゾモルホリンの誘導体
EP2373649B1 (en) 2008-11-28 2013-01-23 Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
WO2010130424A1 (en) 2009-05-12 2010-11-18 Ortho-Mcneil-Janssen Pharmaceuticals, Inc 1,2,3-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
SG176018A1 (en) 2009-05-12 2011-12-29 Janssen Pharmaceuticals Inc 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN103298810B (zh) 2010-11-08 2016-03-16 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
CN103261195B (zh) 2010-11-08 2015-09-02 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
WO2013012918A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
KR20200001619A (ko) 2012-08-06 2020-01-06 피르메니히 인코포레이티드 단맛 향미 개질제
JO3155B1 (ar) 2013-02-19 2017-09-20 Senomyx Inc معدِّل نكهة حلوة
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
KR20200036063A (ko) 2014-01-21 2020-04-06 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
MX386697B (es) 2014-01-21 2025-03-19 Janssen Pharmaceutica Nv Combinaciones que comprenden agonistas ortostericos o moduladores alostericos positivos del receptor glutamatergico metabotropico de subtipo 2 y su uso
ES2749433T3 (es) 2014-06-23 2020-03-20 Celgene Corp Apremilast para el tratamiento de una enfermedad hepática o una anomalía de la función hepática
BR112018012914B1 (pt) 2015-12-22 2023-04-18 SHY Therapeutics LLC Composto, uso de um composto e composição farmacêutica
AU2018288841B2 (en) 2017-06-21 2022-09-29 SHY Therapeutics LLC Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease
MX2021001193A (es) 2018-08-07 2021-04-28 Firmenich Incorporated 2,2-dioxidos de 4-amino-1h-benzo[c][1,2,6]tiadiazina 5-sustituidos y formulaciones y usos de los mismos.
WO2020132071A1 (en) 2018-12-19 2020-06-25 Shy Therapeutics. Llc Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and f1brotic disease
CN116178374B (zh) * 2023-01-13 2024-10-08 河北医科大学 小电导钙激活钾离子通道激动剂及其合成和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1570494A (en) * 1975-11-28 1980-07-02 Ici Ltd Thienopyrimidine derivatives and their use as pesticides
US4196207A (en) * 1977-05-23 1980-04-01 Ici Australia Limited Process for controlling eradicating or preventing infestations of animals by Ixodid ticks
JP2657760B2 (ja) * 1992-07-15 1997-09-24 小野薬品工業株式会社 4−アミノキナゾリン誘導体およびそれを含有する医薬品
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5869486A (en) * 1995-02-24 1999-02-09 Ono Pharmaceutical Co., Ltd. Fused pyrimidines and pyriazines as pharmaceutical compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2261863C2 (ru) * 2000-06-29 2005-10-10 Мерк Патент Гмбх 2-аминоалкилтиено[2,3-d]пиримидины, способ их получения, лекарственный препарат и способ его получения

Also Published As

Publication number Publication date
NO990643L (no) 1999-02-11
HUP0001607A3 (en) 2002-09-30
IL128504A (en) 2003-01-12
CZ44899A3 (cs) 1999-05-12
JP4405593B2 (ja) 2010-01-27
HUP0001607A2 (hu) 2000-10-28
CA2263561C (en) 2007-02-20
EP0920431A1 (de) 1999-06-09
JP2000516223A (ja) 2000-12-05
EP0920431B1 (de) 2003-02-26
BR9711062A (pt) 1999-08-17
PT920431E (pt) 2003-07-31
CN1227560A (zh) 1999-09-01
SK282823B6 (sk) 2002-12-03
WO1998006722A1 (de) 1998-02-19
AU725227B2 (en) 2000-10-12
TW359672B (en) 1999-06-01
PL190174B1 (pl) 2005-11-30
IL128504A0 (en) 2000-01-31
NZ334600A (en) 2000-07-28
PL331538A1 (en) 1999-07-19
UA55421C2 (uk) 2003-04-15
ATE233265T1 (de) 2003-03-15
CN1081638C (zh) 2002-03-27
AU4203597A (en) 1998-03-06
ZA977156B (en) 1998-02-19
DK0920431T3 (da) 2003-06-02
SI0920431T1 (en) 2003-08-31
NO990643D0 (no) 1999-02-11
TR199900308T2 (xx) 1999-04-21
SK16499A3 (en) 1999-06-11
AR009052A1 (es) 2000-03-08
DE59709404D1 (en) 2003-04-03
HK1021731A1 (en) 2000-06-30
KR20000029932A (ko) 2000-05-25
ES2191192T3 (es) 2003-09-01
RU2199541C2 (ru) 2003-02-27
CA2263561A1 (en) 1998-02-19
CZ287772B6 (en) 2001-01-17
US6110920A (en) 2000-08-29
KR100502271B1 (ko) 2005-07-22

Similar Documents

Publication Publication Date Title
DE19632423A1 (de) Thienopyrimidine
WO1998017668A1 (de) Thienopyrimidine mit pde v inhibierender wirkung
EP1036078B1 (de) Thienopyrimidine
EP1337256A2 (de) Verwendung von thienopyrimidinen
EP1210349B1 (de) Pyrazolo[4, 3-d]pyrimidine
EP1084125B1 (de) Kondensierte thienopyrimidine mit pde v inhibierender wirkung
DE19928146A1 (de) Thienopyrimidine
DE10064994A1 (de) Sulfamidothienopyrimidine
EP1355649A2 (de) Pharmazeutische formulierung enthaltend pyrazolo 4,3-d]pyrimidine und nitrate oder thienopyrimidine und nitrate
DE10058662A1 (de) Verwendung von Pyrazolo[4,3-d]pyrimidinen
EP1294729B1 (de) 2-aminoalkyl-thieno[2,3-d]pyrimidine
EP1351962B1 (de) Thienopyrimidine
DE19944604A1 (de) Aminderivate
DE19943815A1 (de) Verwendung von Thienopyrimidinen
MXPA99001387A (en) Thienopyrimidines
DE10104096A1 (de) Pharmazeutische Formulierung enthaltend Thienopyrimidine und Nitrate
DE10104801A1 (de) Pharmazeutische Formulierungen enthaltend Thienopirimidine und Endothelin-Rezeptor-Antagonisten (2)

Legal Events

Date Code Title Description
8139 Disposal/non-payment of the annual fee